MUMBAI, India, June 24 -- Intellectual Property India has published a patent application (202411089376 A) filed by Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act Act Xxi Of on November 18, 2024, for Tricyclic Compound For Breast And Ovarian Cancer Treatment.
Inventors include Dumbala Srinivasa Reddy; Anindya Goswami; Mohd Jamal Dar; Sanket Sanjay Shete; Yashi Garg; Mohmmad Saleem Dar; and Amit Nargotra.
The application for the patent was published on June 12, 2026, under issue no. 24/2026.
Abstract: The present invention relates to a tricyclic compound of formula (I) and its analogue useful for the treatment of breast and ovarian cancer. In particular, the present invention relates to novel tricyclic compound as PARP1/2 inhibitor, which blocks the activity of the enzyme Poly (ADP-ribose) polymerase (PARP1/2), and plays a crucial role in DNA damage repair, particularly in cancer cells. The synthesized inhibitor molecule exhibits improved solubility, bioavailability and no haematological toxicity, which can be useful in potential cancer therapies, and defects in DNA repair pathways.
Disclaimer: Curated by HT Syndication.
